NCT07351669Recruiting
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
The Performance of Spectral CT in Evaluating Treatment Response After Transarterial Chemoembolization for Hepatocellular Carcinoma: The SpecTRAIL Study
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment response following TACE for hepatocellular carcinoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 121 (estimated)
- First submitted
- 29 Dec 2025
- Start date
- 20 Jan 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Zhongda Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07351669
What you commit to
- Study type: Observational
- Planned participants: 121
- From 20 Jan 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- lack of regular CT or MRI follow-up in non-surgical cohort;
Other illness
- presence of extrahepatic malignancy;
Other
- contraindications to contrast-enhanced CT or MRI;
- poor image quality or incomplete clinical data;
- withdrawal from the study.
Who the study is looking for
- age 18-75 years;
- diagnosis of HCC based on pathological findings or accepted clinical and imaging criteria;
- Barcelona Clinic Liver Cancer (BCLC) stage A or B;
- prior treatment with TACE;
- undergoing contrast-enhanced spectral CT at 4-8 weeks after TACE;
- undergoing either liver resection within 1 week after contrast-enhanced spectral CT (surgical cohort) or undergoing hepatic digital subtraction angiography (DSA) or contrast-enhanced MRI within 1 week after contrast-enhanced spectral CT (non-surgical cohort);
- informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongda Hospital Southeast University Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.